Company Encyclopedia
View More
name
Direxion Pharma & Medical Bull 3X
PILL.US
News
View More

With Netflix's 10-for-1 Stock Split Complete, Here Are 3 Growth Stocks to Buy in December That Could Issue Stock Splits in 2026

Netflix completed a 10-for-1 stock split, making shares more accessible at around $100 each. This move could increase Netflix's chances of joining the Dow Jones Industrial Average. Meta Platforms, ASML, and Eli Lilly are predicted to issue stock splits in 2026, making them attractive growth stocks to buy in December. Meta could replace Verizon in the Dow, ASML is poised for technological advancements in AI chips, and Eli Lilly's success is driven by its GLP-1 medications.

Motley Fool·
US
NFLX
-0.71%
US
ASML
-2.70%
US
META
+3.43%
Motley Fool·
US
NFLX
-0.71%
US
ASML
-2.70%
US
META
+3.43%

Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ]

Director Kenneth W. O'Keefe of Jazz Pharmaceuticals Plc surrendered 603 shares back to the company to cover option exercise costs and/or tax liabilities. The transaction was filed with the SEC on December 4, 2025, at a price of $173.07 per share, totaling $104,361. O'Keefe's ending holdings are 30,256 shares, with 25,811 direct and 4,445 indirect.

Reuters·
US
JAZZ
-0.11%
Reuters·
US
JAZZ
-0.11%

Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

Eli Lilly & Co. (LLY) shares fell 1.85% to $1,014.49 on Thursday, marking the sixth consecutive day of losses. The stock underperformed compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. It closed 8.77% below its 52-week high. Trading volume was slightly below the 50-day average. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

Dow Jones·
US
LLY
-1.85%
Dow Jones·
US
LLY
-1.85%

What's Up With The Jump In Viking Therapeutics Stock?

Viking Therapeutics (VKTX) shares rose 11.17% due to excitement in obesity treatment and positive clinical trial developments. The company completed patient enrollment for its Phase 3 VANQUISH-1 trial ahead of schedule, attracting more participants than expected. This momentum is part of a broader interest in GLP-1 and obesity drug developers, with major players like Eli Lilly and Novo Nordisk competing in the market. VKTX shows strong short-term momentum, trading above its 20-day and 200-day SMA, indicating a bullish trend.

fidelity·
US
LLY
-1.85%
US
NVO
+0.88%
US
VKTX
+8.92%
fidelity·
US
LLY
-1.85%
US
NVO
+0.88%
US
VKTX
+8.92%

Top Pharmaceutical Stocks To Add to Your Watchlist - December 4th

MarketBeat highlights Eli Lilly, Novo Nordisk, and Bristol Myers Squibb as top pharmaceutical stocks to watch. These companies offer exposure to healthcare innovation but carry risks related to clinical trials, regulatory approvals, and sector-specific activities. Despite Eli Lilly's moderate buy rating, analysts suggest other stocks may offer better returns.

Market Beat·
US
BMY
+1.94%
US
NVO
+0.88%
US
LLY
-1.85%
Market Beat·
US
BMY
+1.94%
US
NVO
+0.88%
US
LLY
-1.85%
© 2025 Longbridge｜Disclaimer